Biomed-Lublin has a cooperation agreement with the Warsaw Health Innovation Hub

Biomed-Lublin has entered into an agreement with the Warsaw Health Innovation Hub (WHIH) regarding the cooperation of the public sector with business, which is to develop the potential and innovation of Polish medicine, the company said.

"We want to cooperate with, inter alia, with medical universities as well as clinics from all over Poland. We would like to provide our R&D center for the development of BCG mycobacterial products in order to refine their administration in other therapeutic areas. Providing products for clinical trials in new indications is a natural direction and goal of Biomed Lublin, ”said President Maksymilian Świniarski, quoted in the release.

The Warsaw Health Innovation Hub is a joint project of the Medical Research Agency and leading entities in the medicine, pharmacy and biotechnology sector, coordinated by the ABM Department of Innovation and Biotechnology Development. The goal of WHIH is to create innovative medical, technological and legal solutions to improve patients' health and increase the efficiency of the Polish health care system. WHIH is a unique platform for cooperation between economic, public and scientific entities in Central Europe, in order to strengthen the role of Poland as a place for creating medical and biotechnological innovations and increasing the resilience and stability of the health care system after the pandemic.

Biomed-Lublin Wytwórnia Surowic i Szczepionek is a Polish pharmaceutical company operating since 1944. The company produces medicinal preparations (prescription drugs, medical devices and laboratory reagents used in biochemical and medical laboratories). The company has been listed on the main market of the WSE since 2015.

Our privacy policy